Compare · CERS vs SYK
CERS vs SYK
Side-by-side comparison of Cerus Corporation (CERS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $118.01B, about 315.9x CERS ($373.6M).
- CERS has been more active in the news (8 items in the past 4 weeks vs 6 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Stryker Corporation
- Price
- -
- -
- Market cap
- $373.6M
- $118.01B
- 1M return
- -
- +0.99%
- 1Y return
- -
- -16.21%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 8
- 6
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest CERS
- Cerus Corporation to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Cerus Corporation
- Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
- SEC Form S-3 filed by Cerus Corporation
- SEC Form 10-Q filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cerus Corporation Announces Third Quarter 2026 Financial Results
- Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
- Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
- Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
Latest SYK
- Director Ronda E Stryker exercised 3,605 shares at a strike of $122.51, increasing direct ownership by 473% to 4,367 units (SEC Form 4)
- Director Stryker Ronda E sold $178,924,731 worth of shares (550,000 units at $325.32) (SEC Form 4)
- Stryker Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Stryker announces intention to nominate Jim Davis to board of directors
- What 3.4% GDP Growth and a 4.2% Jobless Rate Say About a Hard Day on Wall Street
- SEC Form S-3ASR filed by Stryker Corporation
- SEC Form IRANNOTICE filed by Stryker Corporation
- SEC Form 10-Q filed by Stryker Corporation
- Stryker downgraded by Canaccord Genuity with a new price target
- SEC Form 8-K filed by Stryker Corporation